SecurityHVT / Haverty Furniture Companies, Inc.
Chairman, President & CEOSMITH CLARENCE H
Form 4 Count389
Form 8-K Count56
Form SC 13G/A Count36
Form SC 13D/A Count26

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Haverty Furniture Companies, Inc.


DateFormTitle
2018-05-10 8-K HVT / Haverty Furniture Companies, Inc. null (Current Report)
2018-05-03 10-Q HVT / Haverty Furniture Companies, Inc. null (Quarterly Report)
2018-05-01 8-K HVT / Haverty Furniture Companies, Inc. null (Current Report)
2018-04-10 8-K HVT / Haverty Furniture Companies, Inc. null (Current Report)
2018-03-28 DEF 14A HVT / Haverty Furniture Companies, Inc. null
2018-03-05 8-K HVT / Haverty Furniture Companies, Inc. null (Current Report)
2018-03-02 10-K HVT / Haverty Furniture Companies, Inc. null (Annual Report)
2018-02-21 8-K HVT / Haverty Furniture Companies, Inc. (Current Report)
2018-02-03 8-K HVT / Haverty Furniture Companies, Inc. (Current Report)
2018-01-08 8-K HVT / Haverty Furniture Companies, Inc. (Current Report)
2018-01-03 SC 13D/A HVT / Haverty Furniture Companies, Inc. / H5, L.P. - SCHEDULE 13D (AMENDMENT NO. 11) (Activist Investment)
2018-01-03 SC 13D/A HVT / Haverty Furniture Companies, Inc. / H5, L.P. - SCHEDULE 13D (AMENDMENT NO. 11) (Activist Investment)
2018-01-03 SC 13D/A HVT / Haverty Furniture Companies, Inc. / Villa Clare Partners, LP - SCHEDULE 13D (AMENDMENT NO. 9) (Activist Investment)
2018-01-03 SC 13D/A HVT / Haverty Furniture Companies, Inc. / Villa Clare Partners, LP - SCHEDULE 13D (AMENDMENT NO. 9) (Activist Investment)
2017-12-05 8-K HVT / Haverty Furniture Companies, Inc. (Current Report)
2017-11-08 8-K HVT / Haverty Furniture Companies, Inc. (Current Report)
2017-11-02 10-Q Haverty Furniture Companies (Quarterly Report)
2017-11-01 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-10-06 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-08-02 10-Q Haverty Furniture Companies (Quarterly Report)
2017-08-01 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-05-23 SD Haverty Furniture Companies
2017-05-10 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-05-03 10-Q Haverty Furniture Companies (Quarterly Report)
2017-05-02 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-04-19 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-04-06 DEF 14A Haverty Furniture Companies 14A
2017-03-03 10-K Haverty Furniture Companies (Annual Report)
2017-02-22 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-02-03 8-K Haverty Furniture Companies (Current Report/Significant Event)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 8) (Activist Acquisition of More Than 5% of Shares)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 10) (Activist Acquisition of More Than 5% of Shares)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 7) (Activist Acquisition of More Than 5% of Shares)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 8) (Activist Acquisition of More Than 5% of Shares)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 7) (Activist Acquisition of More Than 5% of Shares)
2017-01-03 SC 13D/A Haverty Furniture Companies SCHEDULE 13D (AMENDMENT NO. 10) (Activist Acquisition of More Than 5% of Shares)
2016-12-06 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-11-02 10-Q Haverty Furniture Companies (Quarterly Report)
2016-11-02 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-08-03 10-Q Haverty Furniture Companies (Quarterly Report)
2016-08-02 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-07-08 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-05-11 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-05-04 10-Q Haverty Furniture Companies (Quarterly Report)
2016-05-03 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-03-30 DEF 14A Haverty Furniture Companies 14A
2016-03-09 8-K/A Haverty Furniture Companies A (Current Report/Significant Event)
2016-03-07 10-K Haverty Furniture Companies (Annual Report)
2016-02-25 8-K Haverty Furniture Companies (Current Report/Significant Event)
2016-02-12 SC 13G/A Haverty Furniture Companies Form SC 13G/A (Acquisition of More Than 5% of Shares)

Related Articles

TROV: TrovaGene Analysis and Research Report

9m - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...